Skip to Content

Krystexxa

Active Substance: pegloticase
Common Name: pegloticase
ATC Code: M04AX02
Marketing Authorisation Holder: Crealta Pharmaceuticals Ireland Limited
Active Substance: pegloticase
Status: Withdrawn
Authorisation Date: 2013-01-08
Therapeutic Area: Gout
Pharmacotherapeutic Group: Antigout preparations

Therapeutic Indication

Krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.

The marketing authorisation for Krystexxa has been withdrawn at the request of the marketing-authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide